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Abstract
Background: Pituitary adenomas have a high disease burden due to tumor growth/
invasion and disordered hormonal secretion. Germline mutations in genes such as MEN1 
and AIP are associated with early onset of aggressive pituitary adenomas that can be 
resistant to medical therapy.
Aims: We performed a retrospective screening study using published risk criteria to 
assess the frequency of AIP and MEN1 mutations in pituitary adenoma patients in a 
tertiary referral center.
Methods: Pituitary adenoma patients with pediatric/adolescent onset, macroadenomas 
occurring ≤30 years of age, familial isolated pituitary adenoma (FIPA) kindreds and 
acromegaly or prolactinoma cases that were uncontrolled by medical therapy were 
studied genetically. We also assessed whether immunohistochemical staining for 
AIP (AIP-IHC) in somatotropinomas was associated with somatostatin analogs (SSA) 
response.
Results: Fifty-five patients met the study criteria and underwent genetic screening for 
AIP/MEN1 mutations. No mutations were identified and large deletions/duplications were 
ruled out using MLPA. In a cohort of sporadic somatotropinomas, low AIP-IHC tumors 
were significantly larger (P = 0.002) and were more frequently sparsely granulated 
(P = 0.046) than high AIP-IHC tumors. No significant relationship between AIP-IHC and 
SSA responses was seen.
Conclusions: Germline mutations in AIP/MEN1 in pituitary adenoma patients are rare and 
the use of general risk criteria did not identify cases in a large tertiary-referral setting. 
In acromegaly, low AIP-IHC was related to larger tumor size and more frequent sparsely 
granulated subtype but no relationship with SSA responsiveness was seen. The genetics 
of pituitary adenomas remains largely unexplained and AIP screening criteria could be 
significantly refined to focus on large, aggressive tumors in young patients.
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Introduction
Clinically apparent pituitary adenomas are present in 
about 1:1000 of the general population in Europe; the 
most frequent sub-types are prolactinomas, non-secreting 
adenomas and somatotropinomas, while Cushing’s 
disease and thyrotropinomas are rarer (1, 2, 3). Treatment 
of pituitary adenomas varies according to the pituitary 
adenoma sub-type. Responses to therapy are variable 
due to heterogeneity among patient profiles and tumor 
characteristics. For instance, acromegaly patients may 
be resistant to somatostatin analogs (SSA) that target the 
somatostatin receptor subtype 2 (SST2), while a small 
proportion of prolactinoma patients may not respond 
to labeled doses of dopamine agonists (DA). Hence, 
multimodal therapy involving neurosurgery, medical 
therapy and radiotherapy can be needed to treat pituitary 
adenomas (4, 5, 6, 7).
There is an increased likelihood of aggressive pituitary 
adenoma characteristics (early age at diagnosis, large 
tumor size, increased invasiveness) in association with 
a number of germline genetic mutations. Of these, the 
aryl hydrocarbon receptor-interacting protein (AIP) 
gene and the MEN1 gene have been widely studied in 
the clinical setting. Germline MEN1 mutations lead to 
multiple endocrine neoplasia type 1 (MEN1), which is 
characterized by tumors occurring in the parathyroids, 
enteropancreatic endocrine tissues and anterior pituitary 
(8). MEN1 mutations can be associated with early onset and 
relatively difficult-to-treat pituitary adenomas (9, 10, 11). 
Germline AIP mutations (AIPmut) or deletions generally 
predispose to acromegaly, usually presenting as familial 
isolated pituitary adenomas (FIPA) (12). Notably, AIPmut-
associated somatotropinomas occur at a significantly 
younger age and are larger and more extensive than 
non-AIPmut acromegaly cases (13). These characteristics 
lead to a high rate of gigantism among AIPmut-affected 
patients (14). AIPmut-associated acromegaly patients have 
a significantly worse response to treatment with SST2-
specific SSA compared with AIP wild-type acromegaly 
controls, both in terms of smaller IGF-1 decreases and less 
tumor shrinkage. In acromegaly patients without AIPmut, 
it has also been suggested that AIP immunohistochemical 
score in surgically-resected somatotropinomas may be a 
good indicator of whether patients are SST2-specific SSA 
responders (15, 16).
Screening studies in the general clinical population 
of pituitary adenomas are not particularly useful as 
AIPmuts are rare (0–4% positive cases) (17, 18, 19). Several 
recommendations have been made regarding the ideal 
characteristics of patients to refer for AIPmut testing, 
including pituitary gigantism patients, FIPA families, 
pediatric pituitary adenoma patients and those with 
pituitary macroadenomas (particularly acromegaly), 
occurring ≤30  years of age (20, 21, 22). Given the 
characteristic resistance to SST2-specific SSA in AIPmut 
acromegaly, it has been suggested that such patients 
might be informative for specific screening. Oriola et al. 
reported that 8% of acromegaly patients who had failed 
surgery and SSA had AIP gene variants (23). To address 
the practicality of these screening factors in the clinical 
setting, we analyzed AIP and MEN1 status in a cohort of 
pituitary adenoma patients from a large regional referral 
population. We also assessed the relationship between 
tumoral immunohistochemical staining for AIP, disease 
characteristics and SST2-specific SSA hormonal responses 
in sporadic acromegaly patients.
Patients and methods
This was a single-center, retrospective study performed in 
patients from the Department of Endocrinology, Hospital 
Universitario Virgen del Rocío, Seville, Spain. Patients 
diagnosed at any time with a pituitary adenoma were 
eligible, up to a cut-off date of July 2017.
Data on each patient included sex, date of birth, age 
at diagnosis, tumor size (maximum diameter), tumor 
classification (micro-or macroadenomas), treatment 
(surgery, medical therapy, radiotherapy) and the 
magnitude of hormonal responses to treatment with SSA 
(including % reduction in IGF-1 from baseline; GH levels 
on an oral glucose tolerance test), where relevant.
Inclusion criteria
We undertook a retrospective analysis of the patient 
population treated for pituitary adenomas who were in 
follow-up at the study center (n = 903).
We identified individuals that fell into the following 
categories:
1. Somatotropinomas and prolactinomas that were 
hormonally resistant to medical treatment.
Patients with documented acromegaly, defined 
as a failure to suppress GH following an oral glucose 
tolerance test, an age/sex-corrected IGF-1 level above 
the upper limit of the normal range and a pituitary 
tumor identified on magnetic resonance imaging 
(MRI) at baseline were assessed. Lack of hormonal 
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control (SSA resistance) was defined as an IGF-1 above 
the upper limit of normal for age and sex, and a non-
suppressed GH following an oral glucose load following 
at least 3  months of treatment with octreotide or 
lanreotide at their maximum labeled/tolerated dose 
in the pre-operative or adjuvant setting. Patients with 
prolactinomas had to have serum prolactin levels 
that were chronically elevated above the upper limit 
of normal in association with a macroadenoma on 
MRI. Lack of hormonal control (DA resistance) was 
defined as per Molitch (17) as a failure to achieve 
normalization of serum prolactin at the highest labeled 
dose of cabergoline (2 mg/week). Resistance to medical 
therapy with SSA or DA in terms of tumor shrinkage 
was not included as a criterion in this study.
2. Early-onset pituitary adenomas of any clinical sub-type.
a. Patients with pituitary tumors that occurred at or 
before 18 years of age (pediatric pituitary tumors). 
Pituitary tumors could be of any clinical subtype 
and of any diameter, as long as a tumor was 
confirmed on MRI at diagnosis; this subgroup also 
included pituitary gigantism patients.
b. Patients with MRI-confirmed pituitary 
macroadenomas that occurred (first symptoms or 
diagnosed) ≤30 years of age.
3. FIPA kindreds.
Patients that had one or more related family 
members with a pituitary adenoma on clinical history 
in the absence of MEN1 or other syndromes.
Genetic studies
Genetic analyses of the AIP and MEN1 genes were 
performed using leukocyte-derived DNA as described 
previously (24). In addition to sequence changes, all 
patients underwent studies to screen for exon-level or 
whole gene deletions or duplications using multiplex 
ligation-dependent probe amplification (MLPA) kit P244 
(SALSA P244 Probemix, MRC-Holland) according to the 
manufacturer’s instructions. In one patient with an AIP 
sequence variant DNA was extracted from the pituitary 
adenoma to test for loss of heterozygosity (LOH) at the 
AIP locus. Sequence variations were assessed and graded 
according to the American College for Medical Genetics 
guidelines. In the case where class 3 (variant of unknown 
significance), class 4 (likely pathogenic) and class 5 
(pathogenic) sequence changes were identified, related 
family members underwent clinical screening for disease 
features and where appropriate, were offered genetic 
testing. Patients provided informed consent for the study, 
which was approved by the Ethics Committees of the CHU 
de Liège and the Hospital Universitario Virgen del Rocío.
Immunohistochemistry for AIP
We undertook a specific study of immunohistochemistry 
for AIP (AIP-IHC) in a series of 51 somatotropinomas 
operated on at the Hospital Universitario Virgen del 
Rocío, Seville, Spain. These 51 patients comprise part of 
a cohort of patients described in Venegas-Moreno et  al. 
(25). All acromegaly patients included in this study were 
surgically pre-treated with SSA (octreotide or lanreotide) 
for >8 weeks, following the usual clinical practice in our 
hospital. IHC was performed using a mouse monoclonal 
anti-AIP antibody (1:500 dilution; NB100-127 (B35-2), 
Bio-Techne R&D Systems S.L.U., Madrid, Spain) as 
described in (16, 26, 27). A semi-quantitative score for 
AIP staining intensity was applied: 0 = negative; 1 = weak; 
2 = moderate; 3 = strong. This was multiplied by a score 
for expression patterning of 1 = patchy and 2 = diffuse to 
provide a final score ranging from 0 to 6. A low overall AIP 
immunostaining result was defined by a semi-quantitative 
AIP-IHC score ≤2, whereas high AIP-IHC was defined as 
a score of ≥3. For Ki-67 quantification, we counted at 
least 1000 cells in an area with the highest cell density. 
Results are expressed as the percentage of tumor cells with 
positive nuclei of the total number of cells. Cytokeratin 
CAM5.2 characteristics and staining pattern were used 
to classify somatotropinomas as sparsely or densely 
granulated tumors. The densely granulated tumors had a 
diffuse perinuclear CAM5.2 staining pattern in >70% of 
tumor cells, while sparsely granulated adenomas had a 
paranuclear and spherical pattern in >70% of cells.
Results
Patient characteristics
As noted in Fig. 1, from a total population of 903 pituitary 
adenoma patients, 67 met the inclusion criteria for the 
genetic study and 55 of these underwent genetic testing. 
Details of the patient population are shown in Table  1. 
Among the 55 participants, there were eight FIPA families; 
seven were two-member families, and one was a three-
member acromegaly-prolactinoma kindred. There were 
12 pediatric pituitary adenoma patients, most of whom 
had Cushing’s disease, while one had gigantism. Fifteen 
patients had a pituitary macroadenoma that presented 
≤30 years of age, 17 patients had SSA-resistant acromegaly 
and three had DA-resistant prolactinomas. The median age 
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at diagnosis of the group was 27 years (range 10–62 years) 
and most patients were female (n = 39). All but five of 
the patients had macroadenomas; four microadenomas 
occurred in children with Cushing’s disease aged 
12–15 years at diagnosis and one was in a FIPA patient.
Genetic results
The screening study was undertaken to assess whether 
patients with the screening criteria had AIP and MEN1 
mutations/deletions, but no pathological genetic variants 
were found in AIP or MEN1 in any of the 55 patients. 
Similarly, on MLPA, no deletions of AIP or MEN1 or 
their individual exons were found. Three subjects were 
heterozygous for the p.D172D AIP variant (rs2276020), 
and one had the p.D44D variant (rs11822907); both 
variants are considered benign or likely benign in nature. 
One patient had the p.A299V (rs148986773) change 
in AIP, which has been reported previously in clinical 
studies. It is considered more likely to be benign, and 
based on tumor DNA studies, we confirmed that there was 
no loss of heterozygosity (LOH) at the AIP locus, which 
further supports this non-pathological classification. 
Family screening demonstrated the p.A299V change 
in an asymptomatic parent and in a sibling. There was 
one MEN1 variant found in one pediatric patient with 
Cushing’s disease, p.R171Q (rs607969), although this too 
is considered as benign/likely benign.
Immunohistochemistry of AIP in sporadic acromegaly
A total of 51 somatotropinomas from sporadic acromegaly 
patients were analyzed. These patients were not selected 
according to tumoral or other disease characteristics 
and their baseline clinical features are shown in Table 2. 
Forty-five tumors were macroadenomas. Nine of the 
adenomas displayed both GH and prolactin expression 
while the remaining 42 were purely GH-secreting tumors. 
Representative images of AIP immunohistochemistry in 
normal pituitary and in somatotropinomas with different 
semiquantitative AIP-IHC scores are shown in Fig.  2. 
All somatotropinomas displayed some degree of AIP 
immunoreactivity. Thus, none of the patients were classified 
as score 0. Twenty-four somatotropinomas exhibited 
low AIP-IHC scores (≤2). Tumor size was significantly 
greater in the low AIP-IHC group (median = 25 mm (IQR, 
15–35.8)) as compared with the high AIP-IHC patients 
(median = 15 mm (IQR, 10–20.3); P = 0.002). No other 
statistically significant differences in gender, age and GH 
or IGF-1 levels at diagnosis were observed between low 
and high AIP-IHC patient groups (Table 2).
Data to determine the response to SSA was available 
for 39 patients at 3  months of treatment (26 before 
surgery and 13 as adjuvant therapy) and for 35 patients 
at 6  months of treatment (18 before surgery and 17 as 
adjuvant therapy). As there were no differences in the 
magnitudes of response to SSA between patients treated 
preoperatively or adjuvantly (25), we analyzed all of the 
SSA response data as a group at 3  months and then at 
6 months. No differences in the percentage reduction in 
IGF-1 were observed between the low and high AIP-IHC 
groups after either 3  or 6 months of SSA treatment (Fig. 2).
Discussion
In this study, we assessed the prevalence of germline 
mutations of AIP and MEN1 in a focused group of 
Figure 1
Disposition of study subjects according to 
screening characteristics.
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55 patients with familial and sporadic isolated pituitary 
adenomas from a large tertiary referral center in Seville, 
Spain. The group was selected based on suggested criteria 
for patients that had a potential for having AIP and 
MEN1 mutations. The study cohort was young overall 
(median age 27  years) with large pituitary adenomas 
(median maximum diameter 22 mm) and included 
eight new FIPA families with 2–3 affected members. 
None of the 55 patients had germline mutations 
in AIP or MEN1 and no cases of AIP/MEN1  
deletions were found.
The results of the current study, while at first glance 
‘negative’, do provide important new and confirmatory 
information. When individual clinical centers are 
considering screening programs for pituitary adenoma 
patients, the relative importance of different proposed 
criteria need to be weighed. As in the current study, 
many new FIPA families can be identified at large tertiary 
Table 2 Baseline characteristics of 51 acromegaly patients studied using AIP immunohistochemistry.
Characteristics Low AIP-IHC High AIP-IHC P-Value
Sex (number, male/female) 11/13M 15/12 0.488
Age at diagnosis (years, median, IQR) 37 (32.5–42.5) 40 (31–48) 0.515
Maximum tumor diameter at diagnosis (mm, median, IQR) 25 (15–35.8) 15 (10–22.3) 0.002
GH at diagnosis (ng/mL, median, IQR) 20.5 (9.9–44.3) 22.5 (8.4–40) 0.852
IGF-1 at diagnosis (%ULN, median, IQR) 280 (238–343) 228 (182–311) 0.163
Treatment duration (months, median, IQR) 6 (2–10.5) 5.5 (2.8–11.5) 0.718
Ki-67 index (%, median, IQR) 0.4 (0.3–1) 0.2 (0.1–1) 0.143
GH-producing histological subtypes (number, sparsely/densely 
granulated)
12/7 9/18 0.046 
Data are presented as medians with interquartile ranges (IQR). Bold indicates statistical significance.
ULN, upper limit of normal for age- and gender-matched IGF-1 levels.
Figure 2
Immunohistochemical detection of AIP in somatotropinomas. Representative images of AIP immunohistochemistry in normal pituitary (A) and 
GH-secreting adenomas showing low (B; diffuse, weak) and high AIP expression (C; patchy, strong). Scale bar: 50 μm in C for A and B. (D) Comparison of 
IGF-1 percent reduction after 3 months of SSA treatment in tumors with low or high AIP-IHC expression. (E) Comparison of IGF-1 percent reduction after 
6 months of SSA treatment with low or high AIP-IHC expression. Data points represent values for each individual patient. Mean and standard error (s.e.m.) 
values are shown.
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-19-0027
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
A F Daly, D A Cano et al. AIP and MEN1 screening in 
pituitary adenomas
345
PB–11
8:4
referral centers, once the family history is specifically 
explored. Most such kindreds will be AIPmut negative, 
as about 80% of FIPA families remain genetically 
unexplained. Pediatric pituitary adenoma series report 
AIPmut rates of 11–20% (28, 29, 30, 31). Most pediatric 
AIPmut-related pituitary adenomas are somatotropinomas 
with occasional prolactinomas or non-functioning 
tumors. Our pediatric cohort showed no AIPmut, which 
is probably because most had Cushing’s disease, which 
confirms our previous findings that Cushing’s disease is 
only very rarely associated with pathological AIPmut (29). 
This study underlines that AIPmut testing in pediatric 
patients with Cushing’s disease has a low likelihood of 
being positive. In pediatric and adolescent patients with 
AIPmut-related pituitary adenomas, a typical presentation 
is with pituitary gigantism. Indeed, AIPmut are the single 
most important cause of pituitary gigantism, explaining 
29% of cases, followed by X-linked acrogigantism (X-LAG) 
syndrome (10%) and McCune Albright syndrome (5%) 
(14). In the current cohort there was only one young 
patient with pituitary gigantism and he was negative for 
not only AIP/MEN1 mutations but also did not have X-LAG 
syndrome on array comparative genome hybridization 
(data not shown).
There is considerable uncertainty about how to best 
define ‘young-onset’ adult pituitary adenoma, with age 
cutoffs of 30 and 40 years having been proposed in the 
past (19, 30, 31). While Preda et  al. found a low rate 
(approximately 3%) of AIPmut in a prospective, single-
center study of patients aged <40  years, we reported a 
higher rate of nearly 12% among an international group 
of sporadic macroadenoma patients aged <30  years at 
diagnosis (19, 30). The contrast between the current 
results and those of our previous multicenter study 
may be explained by the relatively more severe patient 
profile of the AIPmut-positive patients identified in our 
previous study (30). While in the Seville sporadic cohort 
the median age was 27  years and the median tumor 
diameter was 23 mm, in our international study the 
median age at diagnosis (18  years) and maximal tumor 
diameter (39 mm) were indicative of more severe disease. 
It may be that in order to optimize screening, the age of 
adult patients should be revised downward to well below 
30 years at disease onset/diagnosis and that only patients 
with extensive and/or invasive macroadenomas should 
initially be considered for AIPmut analysis.
The topic of standardized screening criteria for AIP 
mutations was considered recently by Caimari et  al. 
(32). They devised a risk stratification assessment for 
genetic screening that confirmed a number of factors 
such as young age at onset (including gigantism), FIPA, 
macroadenomas and GH excess (all P ≤ 0.001). Young age 
at onset (19–30  years) alone was also an independent 
risk factor (P = 0.015). This stratification system points to 
certain very high-risk categories such as FIPA cases with 
macroadenomas occurring up to 18 years of age. In the 
absence of either FIPA, a macroadenoma or an age up 
to 18  years, the risk fell markedly in that stratification 
system. In the case where only moderate risk of an 
AIPmut is present, individual patient characteristics 
become important. In such instances, it is vital to 
take an individualized approach so as not to discount 
aggressive cases of large prolactinomas, non-functioning 
adenomas or apoplexy cases. No general risk stratification 
is foolproof, as shown by our current study: despite 
meeting the criteria for risk of AIPmut like the eight FIPA 
kindreds, no AIPmut cases were seen. Expectations about 
the likelihood of identifying mutation positive cases in 
a hospital cohort must take into account the underlying 
frequency from large collaborative datasets (e.g. only 20% 
of FIPA kindreds are AIPmut positive).
This study addressed whether adding the criteria 
of resistance to medical therapy with first-generation 
SSA in acromegaly patients, or maximum labeled dose 
cabergoline in prolactinoma patients could improve the 
identification of AIP or MEN1 mutations. Resistance to 
first-generation SSA is an established characteristic of 
AIPmut-related acromegaly (13). This may be caused by 
interference with important mediators of SST2 function, 
such as Gai2 or ZAC1 (33, 34). Oriola et  al. previously 
reported a separate Spanish cohort of acromegaly 
patients with SSA resistance and noted a rate of AIPmut 
approaching 8% (23). The current study suggests that 
even in a population of acromegaly patients with 
macroadenomas, the addition of resistance to octreotide 
and lanreotide does not improve detection rates for AIP or 
MEN1 mutations. Given the identification of cabergoline-
resistant prolactinoma patients with AIP and MEN1 
mutations in previous international studies (10, 13, 35), 
we also screened for this criterion in the Seville population 
but only three patients were identified and none carried 
an AIP or MEN1 mutation/deletion.
Previous studies have reported that decreased tumoral 
AIP expression might be associated with poor response 
to first-generation SSA treatment of somatotropinomas, 
although results are inconsistent (15, 16, 26, 33, 36). We 
did not find any such relationship between AIP IHC and 
response to SSA treatment using the same commercial AIP 
antibody and scoring system as in those previous studies. 
A possible explanation for the discrepancy is that all the 
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acromegaly patients included in our IHC study received 
SSA pre-treatment while waiting for surgery. Pre-treatment 
with octreotide/lanreotide in acromegaly is associated 
with increased AIP protein expression (26, 33). Chahal 
et  al. did not find an overall correlation between SSA 
response and AIP IHC in pretreated patients (33). Jaffrain-
Rea et al. reported significantly higher pre-operative GH 
and IGF-1 levels in a group of 67 acromegaly patients with 
low tumoral AIP staining; this difference was, however, not 
seen among a subgroup (n = 25) of patients who had not 
received preoperative SSA treatment (26). Furthermore, 
the only significant differences between low and high 
AIP IHC staining in non-SSA pretreated acromegaly 
patients in that study were in terms of increased 
invasiveness and suprasellar extension associated with 
low AIP staining. These inter-study differences reflect an 
imperfect correlation between AIP IHC and hormonal 
SSA responses. It should be noted that AIP IHC is quite 
variable in somatotropinomas, even among populations 
with germline AIPmut and is a poor tool for screening 
for possible AIPmut cases in a pathological setting (36). 
Given the fact that AIP-IHC results could be biased or 
influenced by SSA pretreatment, as noted earlier, studies 
with well-balanced groups of SSA pretreated and non-
pretreated acromegaly patients would be helpful to clarify 
the role of the effect of SSA pretreatment on AIP-IHC. 
Subsequent studies could also explore the role of AIP-
IHC in predicting control of acromegaly with SSA under 
combined hormonal and tumor shrinkage criteria.
More consistently than predicting hormonal effects 
in acromegaly, low AIP IHC does seem to correlate 
with tumor aggressiveness, invasion and extension in 
somatotropinomas (16, 26). This echoes our finding 
of significantly larger tumor size in low vs high AIP-
IHC acromegaly groups. We also found that sparsely 
granulated adenomas were significantly more frequent 
in the low AIP-IHC group. Sparsely granulated adenomas 
have previously been shown to be associated with lower 
responses to octreotide/lanreotide and better responses to 
pasireotide and they predominate in AIPmut cases (27, 37, 
38). In sporadic acromegaly, it is difficult to know whether 
the relationship between low AIP-IHC and more frequent 
sparsely granulated tumors is a cause or an effect. Specific 
studies to fully explain the means by which AIPmut cause 
somatotrope tumorigenesis will hopefully cast some light 
on this issue.
In conclusion, our understanding of the genetics of 
pituitary adenomas is expanding quickly and many targets 
for screening are emerging. Due to this rapid progress, 
it is difficult to devise concrete guidelines for genetic 
testing in pituitary adenoma populations, although both 
expert recommendations and risk stratification models 
are helpful. While many pituitary adenoma patients 
with AIP and MEN1 mutations have been reported in 
the literature, the current study underlines that in the 
majority of FIPA and sporadic cases, no genetic cause 
is known. Furthermore, SSA resistance did not help to 
identify groups of patients with AIP and MEN1 mutations 
in this study. AIP-IHC is a promising pathological marker 
for somatotropinoma growth and invasion, although 
this study suggests that its role in predicting hormonal 
responses to SSA in acromegaly appears to be limited. 
Improved focus on patients with large and aggressive 
macroadenomas in the setting of pituitary gigantism, 
FIPA and pediatric-onset patients (apart from Cushing’s 
disease) may help to refine genetic testing protocols. 
Nonetheless, other novel genetic factors in pituitary 
tumorigenesis remain to be identified.
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